Need to reduce dependence on bulk drug imports from China: Subburaj

December 23, 2014 04:00 pm | Updated September 02, 2016 01:09 pm IST - New Delhi

A file photo of Pharmaceuticals Secretary V.K. Subburaj. Photo: S. Thanthoni

A file photo of Pharmaceuticals Secretary V.K. Subburaj. Photo: S. Thanthoni

India needs to create a conducive atmosphere for production of bulk drugs to cut dependence on imports from China, a senior government official said in New Delhi on Tuesday.

“We need to create a conducive atmosphere for bulk drugs in the country. We have to reduce our dependence on China for bulk drugs,” Pharmaceuticals Secretary V.K. Subburaj said.

He was speaking on the sidelines of an event organised by think-tank, Research and Information System for Developing Countries (RIS), on India’s growing dependence on imports in the area of bulk drugs.

Stressing on the importance of focusing on domestic bulk drug production, Mr. Subburaj said, “Pharma sector has grown well in our country. It is in the sector of bulk drugs and medical devices where we are dependent on imports.”

The country’s dependence on China for bulk drugs is very high but it can come out of it, he added.

“We have to ensure that we don’t depend on a single source. In 10 years time we should be able to say we are not dependent on anyone for bulk drugs,” Mr. Subburaj said.

National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad will have a bulk drug research and development centre to take care of bulk drugs, he added.

The government is also planning many other initiatives to further strengthen the pharma sector, Mr. Subburaj said.

Last month, Union Chemicals and Fertilisers Minister Ananth Kumar had told Parliament that India was largely dependent on China for imports of drug ingredients of 12 essential drugs which are in the National List of Essential Medicines (NLEM).

The Minister had said that the government has decided to work out a package of interventions and concessions required to build domestic production capabilities in this regard and examine the cost implication.

A decision has been taken to set up a Committee of Secretaries under the Chairmanship of Secretary, Department of Health Research to study and identify the active pharmaceutical ingredients (APIs) of critical importance, Mr. Kumar had said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.